The restraining order related to alleged infringement of Oxandrin patents held by Savient. Oxandrin is an oral anabolic agent indicated as adjunctive therapy to promote weight gain and is also indicated for patients who fail to gain or maintain normal weight. Oxandrin can also be used to offset the protein catabolism associated with prolonged corticosteroid use.
However, the court has also certified a legal issue for appeal by Savient, although the opinion underlying the order has not yet been made available.
“We look forward to receiving and studying the court’s opinion in order to understand better what the court has directed and to determine the next actions and steps that may be available to us in defending our patent rights related to the use of Oxandrin,” said Christopher Clement, president and CEO of Savient.